Cargando…
Safety of Repeated Open-Label Treatment Courses of Intravenous Ofatumumab, a Human Anti-CD20 Monoclonal Antibody, in Rheumatoid Arthritis: Results from Three Clinical Trials
OBJECTIVES: To investigate the safety of ofatumumab retreatment in rheumatoid arthritis. METHODS: Patients with active rheumatoid arthritis participating in two phase III trials (OFA110635 and OFA110634) and a phase II extension trial (OFA111752) received individualised open-label ofatumumab retreat...
Autores principales: | Quattrocchi, Emilia, Østergaard, Mikkel, Taylor, Peter C., van Vollenhoven, Ronald F., Chu, Myron, Mallett, Stephen, Perry, Hayley, Kurrasch, Regina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4919033/ https://www.ncbi.nlm.nih.gov/pubmed/27336685 http://dx.doi.org/10.1371/journal.pone.0157961 |
Ejemplares similares
-
Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomised, double-blind, placebo-controlled clinical trial
por: Taylor, Peter C, et al.
Publicado: (2011) -
Ofatumumab: a novel monoclonal anti-CD20 antibody
por: Lin, Thomas S
Publicado: (2010) -
Distribution and efficacy of ofatumumab and ocrelizumab in humanized CD20 mice following subcutaneous or intravenous administration
por: Torres, Julia Baguña, et al.
Publicado: (2022) -
Ofatumumab Monoclonal Antibody Affinity Maturation Through in silico Modeling
por: Payandeh, Zahra, et al.
Publicado: (2018) -
The Development of Ofatumumab, a Fully Human Anti-CD20 Monoclonal Antibody for Practical Use in Relapsing Multiple Sclerosis Treatment
por: Hauser, Stephen L., et al.
Publicado: (2023)